1. Scrip
  2. >>Focus On Asia
  3. >>China

Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?

Companies Hope Volumes Will Offset Sharply Lower Prices

 
• By Brian Yang

Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.

US dollar and Yuan China which its are 2 biggest countries for economic growth.Now America and China announce tariff tax policy to make conflict.
DEEP PRICE CUTS TO GAIN REIMBURSEMENT IN CHINA LIST REVAMP • Source: Shutterstock

Some globally well-known drugs are now being offered at prices affordable to the common public in China, precisely what the country’s Medical Insurance and Support Administration had in mind when announcing an updated National Reimbursement Drug List (NRDL) on 28 November.

Out of 119 novel drugs that newly qualified for the coverage, 70 were eventually added to the list, meaning they are reimbursed by the national medical insurance program. The cost of the addition was a 60.7% average price reduction across the board but the steepest cuts ranged up to more than 85% for hepatitis C regimens

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.